What is the appropriate evaluation and management for a 15 mm thyroid nodule in an adult?

Evaluation and Management of a 15 mm Thyroid Nodule

A 15 mm thyroid nodule requires ultrasound risk stratification followed by ultrasound-guided fine-needle aspiration (FNA) if it demonstrates high-risk features (EU-TIRADS 5/Class 3) or intermediate-risk features (EU-TIRADS 4/Class 2 if >20 mm), with subsequent management determined by cytology results. 1

Initial Evaluation

Laboratory Assessment

• Measure serum TSH as the first-line laboratory test to assess thyroid function and guide subsequent testing 1, 2
• If TSH is suppressed, measure free T4 and free T3 1
• If TSH is elevated, measure thyroid peroxidase antibodies (TPOAbs) and free T4 1
• Do not routinely measure serum calcitonin unless medullary thyroid carcinoma is suspected based on family history or cytology results 1, 3

Ultrasound Risk Stratification

All patients with a palpable nodule or clinical risk factors must undergo high-resolution thyroid ultrasound to characterize the nodule and assign a malignancy risk category 1, 2

The nodule should be classified into one of three risk categories based on sonographic features 1:

Class 3 (High-Risk) - 50-90% malignancy risk:

• Marked hypoechogenicity (compared to prethyroid muscles)
• Spiculated or microlobulated margins
• Microcalcifications
• Taller-than-wide shape
• Evidence of extrathyroidal growth or pathologic adenopathy 1

Class 2 (Intermediate-Risk) - 5-15% malignancy risk:

• Slightly hypoechoic nodules with ovoid-to-round shape
• Smooth or ill-defined margins
• May have intranodular vascularization, elevated stiffness, or rim calcifications 1

Class 1 (Low-Risk) - ~1% malignancy risk:

• Mostly cystic (>50%) with reverberating artifacts
• Isoechoic spongiform appearance
• Regular halo 1

FNA Decision Algorithm for 15 mm Nodule

High-Risk Nodules (Class 3/EU-TIRADS 5)

Perform ultrasound-guided FNA immediately - all high-risk nodules ≥10 mm require biopsy 1, 2, 3

Intermediate-Risk Nodules (Class 2/EU-TIRADS 4)

FNA is NOT indicated at 15 mm - intermediate-risk nodules require FNA only when >20 mm 1, 2

• Monitor with ultrasound surveillance instead
• Perform FNA if the nodule grows beyond 20 mm 1

Low-Risk Nodules (Class 1/EU-TIRADS 2-3)

FNA is NOT indicated at 15 mm - low-risk nodules require FNA only when ≥20 mm AND showing progressive growth or associated with risk history 1, 2

Special Circumstances Requiring FNA Regardless of Risk Category

Even if the nodule appears intermediate or low-risk, perform FNA at 15 mm if any of the following are present 1, 3:

• Subcapsular or paratracheal location
• Suspicious cervical lymph nodes
• Personal or family history of thyroid cancer
• History of head/neck radiation exposure
• Coexistent suspicious clinical findings (dysphonia, dysphagia, rapid growth) 1, 3, 4

FNA Technical Requirements

All FNA procedures must be performed under real-time ultrasound guidance - this is mandatory, not optional, as it improves safety, reliability, and reduces nondiagnostic rates 1, 3

Sampling Technique

• Use 23-27 gauge needles 3
• Sample at least two distinct sites within the nodule to reduce false-negative results 1, 3
• For complex nodules, target the solid, vascularized component 1, 3
• Submit both FNA specimen and any drained fluid for cytologic examination 1

Management Based on Cytology Results

Benign (Bethesda II)

• Clinical and ultrasound surveillance - no treatment required 1
• Repeat FNA only if suspicious ultrasound features develop or nodule volume increases >50% 1
• Levothyroxine suppressive therapy is NOT recommended for benign nodules in euthyroid patients 1, 2

Nondiagnostic (Bethesda I)

• Repeat ultrasound-guided FNA after 1-3 months 3
• If persistently nondiagnostic after second attempt, consider core-needle biopsy 1, 3

Indeterminate (Bethesda III-IV)

• Low-risk indeterminate (AUS/FLUS): Consider repeat FNA, molecular testing, or conservative management based on clinical and ultrasound features 1
• High-risk indeterminate (FN/SFN): Surgery is recommended - thyroid lobectomy plus isthmusectomy is the standard approach 1

Suspicious or Malignant (Bethesda V-VI)

Surgical treatment is recommended 1

• Preoperative ultrasound evaluation of cervical lymph nodes 1
• Extent of surgery determined by tumor characteristics and patient factors 1

Surveillance Strategy for Non-Biopsied Nodules

For nodules that do not meet FNA criteria at 15 mm:

• First follow-up ultrasound at 1-2 years 3
• If stable, subsequent scans every 2-4 years 3
• Some evidence supports initial reassessment delayed to 3 years for stable nodules 3

Critical Pitfalls to Avoid

• Never perform FNA without ultrasound guidance, even for palpable nodules - this markedly reduces diagnostic accuracy 3
• Do not biopsy functioning ("hot") nodules on scintigraphy that lack suspicious ultrasound features 1, 2, 3
• Do not rely on nodule size alone - always integrate ultrasound risk features into decision-making 3
• Do not biopsy more than two nodules in the same patient 1
• Avoid annual routine biopsies of stable nodules with benign cytology - this constitutes overutilization without improving outcomes 3